Overcoming biological barriers by virus-like drug particles for drug delivery

Adv Drug Deliv Rev. 2023 Dec:203:115134. doi: 10.1016/j.addr.2023.115134. Epub 2023 Nov 4.

Abstract

Virus-like particles (VLPs) have natural structural antigens similar to those found in viruses, making them valuable in vaccine immunization. Furthermore, VLPs have demonstrated significant potential in drug delivery, and emerged as promising vectors for transporting chemical drug, genetic drug, peptide/protein, and even nanoparticle drug. With virus-like permeability and strong retention, they can effectively target specific organs, tissues or cells, facilitating efficient intracellular drug release. Further modifications allow VLPs to transfer across various physiological barriers, thus acting the purpose of efficient drug delivery and accurate therapy. This article provides an overview of VLPs, covering their structural classifications, deliverable drugs, potential physiological barriers in drug delivery, strategies for overcoming these barriers, and future prospects.

Keywords: Drug delivery; Physiological barriers; Strategies; Virus-like particles (VLPs).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens
  • Drug Delivery Systems
  • Humans
  • Pharmaceutical Preparations
  • Vaccines, Virus-Like Particle*
  • Viruses*

Substances

  • Pharmaceutical Preparations
  • Antigens
  • Vaccines, Virus-Like Particle